%0 Journal Article %A Anita A. Shah %A Florien Dusseldorp %A Irene K. Veldhuijzen %A Margreet J.M. te Wierik %A Alvin Bartels %A Jack Schijven %A Lucie C. Vermeulen %A Mirjam J. Knol %T High SARS-CoV-2 attack rates following exposure during singing events in the Netherlands, September-October 2020 %D 2021 %R 10.1101/2021.03.30.21253126 %J medRxiv %P 2021.03.30.21253126 %X Previous reports indicate that there may be an increased risk of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission during singing events. We describe SARS-CoV-2 transmission in six singing events from September–October 2020, across the Netherlands, with attack rates from 25–74%. We investigated potential routes of SARS-CoV-2 transmission for each event. Events included 9–21 persons, aged 20–79 years. SARS-CoV-2 transmission likely took place during five out of six events; a possible index case could be identified in four out of five clusters. Limited sequencing data was available, hampering interpretation of results. Indirect contact and droplet transmission (<1.5m) may have caused some cases, but are unlikely to explain the high attack rates. The previously published AirCoV2 model indicated that airborne transmission (via infectious droplets/ aerosols over longer distances (>1.5m)) due to singing is possible in case of supershedder presence (≥1010 RNA copies/mL). Also, airflow expelling respiratory droplets over longer distances (>1.5m) may have influenced transmission. In conclusion, a combination of transmission routes probably caused these five clusters. Proportions attributable to each route cannot be deduced. It is possible that airborne transmission of SARS-CoV-2 due to singing (partly) led to the high attack rates observed in these clusters.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Centre for Clinical Expertise (KEC) at the RIVM assessed the study and verified whether the work complies with the specific conditions as stated in the law for medical research involving human subjects (WMO). It was decided that the research does not fulfill these conditions and therefore concluded that it is exempted for further approval by the ethical research committee. The study was carried out in accordance with the Dutch Public Health Act. Participation in the questionnaire was voluntary and online informed consent was obtained.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated during and/or analysed during the current study are not publicly available but are available from the corresponding author on reasonable request. %U https://www.medrxiv.org/content/medrxiv/early/2021/04/06/2021.03.30.21253126.full.pdf